PubMed

Protein kinase C{beta} modulates ligand-induced cell surface death receptor accumulation: A mechanistic basis for enzastaurin-death ligand synergy.

Meng XW, Heldebrant MP, Flatten KS, Loegering DA, Dai H, Schneider PA, Gomez TS, Peterson KL, Trushin SA, Hess AD, Smith BD, Karp JE, Billadeau DD, Kaufmann SH.

J Biol Chem. 2009 Nov 3. [Epub ahead of print]PMID: 19887445 [PubMed - as supplied by publisher]Related articlesFree article

Progressive chromatin repression and promoter methylation of CTNNA1 associated with advanced myeloid malignancies.

Ye Y, McDevitt MA, Guo M, Zhang W, Galm O, Gore SD, Karp JE, Maciejewski JP, Kowalski J, Tsai HL, Gondek LP, Tsai HC, Wang X, Hooker C, Smith BD, Carraway HE, Herman JG.

Cancer Res. 2009 Nov 1;69(21):8482-90. Epub 2009 Oct 13.PMID: 19826047 [PubMed - in process]Related articles

Expression of insulin receptor isoform A and insulin-like growth factor-1 receptor in human acute myelogenous leukemia: effect of the dual-receptor inhibitor BMS-536924 in vitro.

Wahner Hendrickson AE, Haluska P, Schneider PA, Loegering DA, Peterson KL, Attar R, Smith BD, Erlichman C, Gottardis M, Karp JE, Carboni JM, Kaufmann SH.

Cancer Res. 2009 Oct 1;69(19):7635-43. Epub 2009 Sep 29.PMID: 19789352 [PubMed - in process]Related articles

What are the endpoints of therapy for acute leukemias? Old definitions and new challenges.

Smith BD, Karp JE.

Clin Lymphoma Myeloma. 2009;9 Suppl 3:S296-301.PMID: 19778856 [PubMed - in process]Related articles

New lesions detected by single nucleotide polymorphism array-based chromosomal analysis have important clinical impact in acute myeloid leukemia.

Tiu RV, Gondek LP, O'Keefe CL, Huh J, Sekeres MA, Elson P, McDevitt MA, Wang XF, Levis MJ, Karp JE, Advani AS, Maciejewski JP.

J Clin Oncol. 2009 Nov 1;27(31):5219-26. Epub 2009 Sep 21.PMID: 19770377 [PubMed - indexed for MEDLINE]Related articles

Tipifarnib in the treatment of newly diagnosed acute myelogenous leukemia.

Karp JE, Lancet JE.

Biologics. 2008 Sep;2(3):491-500.PMID: 19707379 [PubMed - in process]Related articlesFree article

New agents in acute myeloid leukemia: beyond cytarabine and anthracyclines.

Fathi AT, Karp JE.

Curr Oncol Rep. 2009 Sep;11(5):346-52.PMID: 19679009 [PubMed - in process]Related articles

Phase I/II trial of AEG35156 X-linked inhibitor of apoptosis protein antisense oligonucleotide combined with idarubicin and cytarabine in patients with relapsed or primary refractory acute myeloid leukemia.

Schimmer AD, Estey EH, Borthakur G, Carter BZ, Schiller GJ, Tallman MS, Altman JK, Karp JE, Kassis J, Hedley DW, Brandwein J, Xu W, Mak DH, LaCasse E, Jacob C, Morris SJ, Jolivet J, Andreeff M.

J Clin Oncol. 2009 Oct 1;27(28):4741-6. Epub 2009 Aug 3.PMID: 19652057 [PubMed - indexed for MEDLINE]Related articles

Novel postremission strategies in adults with acute myeloid leukemia.

Lancet JE, Karp JE.

Curr Opin Hematol. 2009 Mar;16(2):105-11. Review.PMID: 19468272 [PubMed - indexed for MEDLINE]Related articles

Active oral regimen for elderly adults with newly diagnosed acute myelogenous leukemia: a preclinical and phase 1 trial of the farnesyltransferase inhibitor tipifarnib (R115777, Zarnestra) combined with etoposide.

Karp JE, Flatten K, Feldman EJ, Greer JM, Loegering DA, Ricklis RM, Morris LE, Ritchie E, Smith BD, Ironside V, Talbott T, Roboz G, Le SB, Meng XW, Schneider PA, Dai NT, Adjei AA, Gore SD, Levis MJ, Wright JJ, Garrett-Mayer E, Kaufmann SH.

Blood. 2009 May 14;113(20):4841-52. Epub 2008 Dec 24.PMID: 19109557 [PubMed - indexed for MEDLINE]Related articles

A pharmacodynamic study of the FLT3 inhibitor KW-2449 yields insight into the basis for clinical response.

Pratz KW, Cortes J, Roboz GJ, Rao N, Arowojolu O, Stine A, Shiotsu Y, Shudo A, Akinaga S, Small D, Karp JE, Levis M.

Blood. 2009 Apr 23;113(17):3938-46. Epub 2008 Nov 24.PMID: 19029442 [PubMed - indexed for MEDLINE]Related articlesFree article

The long road to a cure for acute myelocytic leukemia: from intensity to specificity.

Vaughan WP, Karp JE.

J Clin Oncol. 2008 Jul 20;26(21):3475-7. No abstract available. PMID: 18640926 [PubMed - indexed for MEDLINE]Related articles

Phase II trial of tipifarnib as maintenance therapy in first complete remission in adults with acute myelogenous leukemia and poor-risk features.

Karp JE, Smith BD, Gojo I, Lancet JE, Greer J, Klein M, Morris L, Levis MJ, Gore SD, Wright JJ, Garrett-Mayer E.

Clin Cancer Res. 2008 May 15;14(10):3077-82.PMID: 18483374 [PubMed - indexed for MEDLINE]Related articlesFree article

Prevention and treatment of cancer-related infections.

Segal BH, Freifeld AG, Baden LR, Brown AE, Casper C, Dubberke E, Gelfand M, Greene JN, Ison MG, Ito JI, Karp JE, Kaul DR, King E, Mackler E, Marcucci G, Montoya JG, Engemann AM, Rolston K, The AS.

J Natl Compr Canc Netw. 2008 Feb;6(2):122-74. Review. No abstract available. PMID: 18319048 [PubMed - indexed for MEDLINE]Related articles

A 2-gene classifier for predicting response to the farnesyltransferase inhibitor tipifarnib in acute myeloid leukemia.

Raponi M, Lancet JE, Fan H, Dossey L, Lee G, Gojo I, Feldman EJ, Gotlib J, Morris LE, Greenberg PL, Wright JJ, Harousseau JL, Löwenberg B, Stone RM, De Porre P, Wang Y, Karp JE.

Blood. 2008 Mar 1;111(5):2589-96. Epub 2007 Dec 26.PMID: 18160667 [PubMed - indexed for MEDLINE]Related articlesFree article

Development of farnesyltransferase inhibitors for clinical cancer therapy: focus on hematologic malignancies.

Karp JE, Lancet JE.

Cancer Invest. 2007 Sep;25(6):484-94. Review.PMID: 17882662 [PubMed - indexed for MEDLINE]Related articles

Mcl-1 as a buffer for proapoptotic Bcl-2 family members during TRAIL-induced apoptosis: a mechanistic basis for sorafenib (Bay 43-9006)-induced TRAIL sensitization.

Meng XW, Lee SH, Dai H, Loegering D, Yu C, Flatten K, Schneider P, Dai NT, Kumar SK, Smith BD, Karp JE, Adjei AA, Kaufmann SH.

J Biol Chem. 2007 Oct 12;282(41):29831-46. Epub 2007 Aug 13.PMID: 17698840 [PubMed - indexed for MEDLINE]Related articlesFree article

Sequential flavopiridol, cytosine arabinoside, and mitoxantrone: a phase II trial in adults with poor-risk acute myelogenous leukemia.

Karp JE, Smith BD, Levis MJ, Gore SD, Greer J, Hattenburg C, Briel J, Jones RJ, Wright JJ, Colevas AD.

Clin Cancer Res. 2007 Aug 1;13(15 Pt 1):4467-73.PMID: 17671131 [PubMed - indexed for MEDLINE]Related articlesFree article

A phase I study of the novel ribonucleotide reductase inhibitor 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, Triapine) in combination with the nucleoside analog fludarabine for patients with refractory acute leukemias and aggressive myeloproliferative disorders.

Karp JE, Giles FJ, Gojo I, Morris L, Greer J, Johnson B, Thein M, Sznol M, Low J.

Leuk Res. 2008 Jan;32(1):71-7. Epub 2007 Jul 20.PMID: 17640728 [PubMed - indexed for MEDLINE]Related articlesFree article

Induction of acute lymphocytic leukemia differentiation by maintenance therapy.

Lin TL, Vala MS, Barber JP, Karp JE, Smith BD, Matsui W, Jones RJ.

Leukemia. 2007 Sep;21(9):1915-20. Epub 2007 Jul 5.PMID: 17611566 [PubMed - indexed for MEDLINE]Related articlesFree article

A phase 1 clinical-laboratory study of clofarabine followed by cyclophosphamide for adults with refractory acute leukemias.

Karp JE, Ricklis RM, Balakrishnan K, Briel J, Greer J, Gore SD, Smith BD, McDevitt MA, Carraway H, Levis MJ, Gandhi V.

Blood. 2007 Sep 15;110(6):1762-9. Epub 2007 Jun 11.PMID: 17562873 [PubMed - indexed for MEDLINE]Related articlesFree article

Phase I and pharmacokinetic study of Triapine, a potent ribonucleotide reductase inhibitor, in adults with advanced hematologic malignancies.

Gojo I, Tidwell ML, Greer J, Takebe N, Seiter K, Pochron MF, Johnson B, Sznol M, Karp JE.

Leuk Res. 2007 Sep;31(9):1165-73. Epub 2007 Feb 26.PMID: 17324462 [PubMed - indexed for MEDLINE]Related articles

Fluorescent in situ hybridization (FISH) in bone marrow and peripheral blood of leukemia patients: implications for occupational surveillance.

McDevitt MA, Condon M, Stamberg J, Karp JE, McDiarmid M.

Mutat Res. 2007 Apr 20;629(1):24-31. Epub 2007 Jan 10.PMID: 17276720 [PubMed - indexed for MEDLINE]Related articles

Phase 1 and pharmacologic study of MS-275, a histone deacetylase inhibitor, in adults with refractory and relapsed acute leukemias.

Gojo I, Jiemjit A, Trepel JB, Sparreboom A, Figg WD, Rollins S, Tidwell ML, Greer J, Chung EJ, Lee MJ, Gore SD, Sausville EA, Zwiebel J, Karp JE.

Blood. 2007 Apr 1;109(7):2781-90.PMID: 17179232 [PubMed - indexed for MEDLINE]Related articlesFree article

A phase 2 study of the farnesyltransferase inhibitor tipifarnib in poor-risk and elderly patients with previously untreated acute myelogenous leukemia.

Lancet JE, Gojo I, Gotlib J, Feldman EJ, Greer J, Liesveld JL, Bruzek LM, Morris L, Park Y, Adjei AA, Kaufmann SH, Garrett-Mayer E, Greenberg PL, Wright JJ, Karp JE.

Blood. 2007 Feb 15;109(4):1387-94. Epub 2006 Nov 2.PMID: 17082323 [PubMed - indexed for MEDLINE]Related articlesFree article

Plasma inhibitory activity (PIA): a pharmacodynamic assay reveals insights into the basis for cytotoxic response to FLT3 inhibitors.

Levis M, Brown P, Smith BD, Stine A, Pham R, Stone R, Deangelo D, Galinsky I, Giles F, Estey E, Kantarjian H, Cohen P, Wang Y, Roesel J, Karp JE, Small D.

Blood. 2006 Nov 15;108(10):3477-83. Epub 2006 Jul 20.PMID: 16857987 [PubMed - indexed for MEDLINE]Related articlesFree article

Combined DNA methyltransferase and histone deacetylase inhibition in the treatment of myeloid neoplasms.

Gore SD, Baylin S, Sugar E, Carraway H, Miller CB, Carducci M, Grever M, Galm O, Dauses T, Karp JE, Rudek MA, Zhao M, Smith BD, Manning J, Jiemjit A, Dover G, Mays A, Zwiebel J, Murgo A, Weng LJ, Herman JG.

Cancer Res. 2006 Jun 15;66(12):6361-9.PMID: 16778214 [PubMed - indexed for MEDLINE]Related articlesFree article

JAK2 V617F is a rare finding in de novo acute myeloid leukemia, but STAT3 activation is common and remains unexplained.

Steensma DP, McClure RF, Karp JE, Tefferi A, Lasho TL, Powell HL, DeWald GW, Kaufmann SH.

Leukemia. 2006 Jun;20(6):971-8.PMID: 16598306 [PubMed - indexed for MEDLINE]Related articles

Factors affecting the pharmacokinetic profile of MS-275, a novel histone deacetylase inhibitor, in patients with cancer.

Acharya MR, Karp JE, Sausville EA, Hwang K, Ryan Q, Gojo I, Venitz J, Figg WD, Sparreboom A.

Invest New Drugs. 2006 Sep;24(5):367-75.PMID: 16583304 [PubMed - indexed for MEDLINE]Related articles

Exploiting oxidative damage to overcome resistance.

Karp JE, Smith BD.

Leuk Res. 2006 Oct;30(10):1213-4. Epub 2006 Mar 27. No abstract available. PMID: 16564572 [PubMed - indexed for MEDLINE]Related articles

Development of the farnesyltransferase inhibitor tipifarnib for therapy of hematologic malignancies.

Karp JE, Lancet JE.

Future Oncol. 2005 Dec;1(6):719-31. Review.PMID: 16556050 [PubMed - indexed for MEDLINE]Related articles

Developmental clinical trials: building one step at a time.

Karp JE, Smith BD.

Leuk Res. 2006 Jul;30(7):765-6. Epub 2006 Feb 20. No abstract available. PMID: 16490252 [PubMed - indexed for MEDLINE]Related articles

Phase I and pharmacokinetic study of flavopiridol followed by 1-beta-D-arabinofuranosylcytosine and mitoxantrone in relapsed and refractory adult acute leukemias.

Karp JE, Passaniti A, Gojo I, Kaufmann S, Bible K, Garimella TS, Greer J, Briel J, Smith BD, Gore SD, Tidwell ML, Ross DD, Wright JJ, Colevas AD, Bauer KS.

Clin Cancer Res. 2005 Dec 1;11(23):8403-12.PMID: 16322302 [PubMed - indexed for MEDLINE]Related articlesFree article

Targeting the process of farynesylation for therapy of hematologic malignancies.

Karp JE, Lancet JE.

Curr Mol Med. 2005 Nov;5(7):643-52. Review.PMID: 16305490 [PubMed - indexed for MEDLINE]Related articles

Farnesyl transferase inhibition in hematologic malignancies.

Karp JE.

J Natl Compr Canc Netw. 2005 Nov;3 Suppl 1:S37-40. No abstract available. PMID: 16280111 [PubMed - indexed for MEDLINE]Related articles

Histone deacetylase inhibitor pharmacodynamic analysis by multiparameter flow cytometry.

Chung EJ, Lee S, Sausville EA, Ryan Q, Karp JE, Gojo I, Telford WG, Lee MJ, Kong HS, Trepel JB.

Ann Clin Lab Sci. 2005 Autumn;35(4):397-406.PMID: 16254255 [PubMed - indexed for MEDLINE]Related articles

New concepts in the treatment of acute myeloid malignancies: selected pathways for targeted therapy.

Smith BD, Bao T, Karp JE.

J Biol Regul Homeost Agents. 2005 Jan-Jun;19(1-2):23-32. Review.PMID: 16178271 [PubMed - indexed for MEDLINE]Related articles

New agents in the treatment of acute myeloid leukemia: a snapshot of signal transduction modulation.

Bao T, Smith BD, Karp JE.

Clin Adv Hematol Oncol. 2005 Apr;3(4):287-96, 302. Review.PMID: 16167001 [PubMed - indexed for MEDLINE]Related articles

Phase I and pharmacologic study of infusional topotecan and Carboplatin in relapsed and refractory acute leukemia.

Kaufmann SH, Karp JE, Letendre L, Kottke TJ, Safgren S, Greer J, Gojo I, Atherton P, Svingen PA, Loegering DA, Litzow MR, Sloan JA, Reid JM, Ames MM, Adjei AA, Erlichman C.

Clin Cancer Res. 2005 Sep 15;11(18):6641-9.PMID: 16166443 [PubMed - indexed for MEDLINE]Related articlesFree article

Farnesyl transferase inhibitors in myeloid disorders.

Lancet JE, Karp JE.

Oncology (Williston Park). 2005 Jul;19(8):1043-9; discussion 1049-50, 1053-4. Review.PMID: 16131046 [PubMed - indexed for MEDLINE]Related articles

Durable molecular remissions with a single cycle of timed sequential consolidation chemotherapy in acute promyelocytic leukemia.

Gore SD, Smith BD, Gojo I, Grever M, Kaufmann SH, Letendre L, Leonard DG, Marcucci G, Miller CB, Morris L, Piantadosi S, Prior T, Stock W, Karp JE.

Am J Hematol. 2005 Jun;79(2):119-27.PMID: 15929100 [PubMed - indexed for MEDLINE]Related articles

Curing acute myelogenous leukemia: still a major challenge.

Smith BD, Karp JE.

Leuk Res. 2005 Jun;29(6):607-8. Epub 2005 Mar 29. No abstract available. PMID: 15863198 [PubMed - indexed for MEDLINE]Related articles

Trying to improve clinical outcome in AML: lessons from negative trials.

Karp JE, Smith BD.

Leuk Res. 2005 Jun;29(6):603-4. Epub 2005 Mar 16. No abstract available. PMID: 15863196 [PubMed - indexed for MEDLINE]Related articles

Heat shock protein 90 inhibition sensitizes acute myelogenous leukemia cells to cytarabine.

Mesa RA, Loegering D, Powell HL, Flatten K, Arlander SJ, Dai NT, Heldebrant MP, Vroman BT, Smith BD, Karp JE, Eyck CJ, Erlichman C, Kaufmann SH, Karnitz LM.

Blood. 2005 Jul 1;106(1):318-27. Epub 2005 Mar 22.PMID: 15784732 [PubMed - indexed for MEDLINE]Related articlesFree article

A phase I and pharmacologic study of idarubicin, cytarabine, etoposide, and the multidrug resistance protein (MDR1/Pgp) inhibitor PSC-833 in patients with refractory leukemia.

Bauer KS, Karp JE, Garimella TS, Wu S, Tan M, Ross DD.

Leuk Res. 2005 Mar;29(3):263-71.PMID: 15661261 [PubMed - indexed for MEDLINE]Related articles

Epigenetic and genetic loss of Hic1 function accentuates the role of p53 in tumorigenesis.

Chen W, Cooper TK, Zahnow CA, Overholtzer M, Zhao Z, Ladanyi M, Karp JE, Gokgoz N, Wunder JS, Andrulis IL, Levine AJ, Mankowski JL, Baylin SB.

Cancer Cell. 2004 Oct;6(4):387-98.PMID: 15488761 [PubMed - indexed for MEDLINE]Related articles

Microarray analysis reveals genetic pathways modulated by tipifarnib in acute myeloid leukemia.

Raponi M, Belly RT, Karp JE, Lancet JE, Atkins D, Wang Y.

BMC Cancer. 2004 Aug 25;4:56.PMID: 15329151 [PubMed - indexed for MEDLINE]Related articlesFree article

Targeting vascular endothelial growth factor for relapsed and refractory adult acute myelogenous leukemias: therapy with sequential 1-beta-d-arabinofuranosylcytosine, mitoxantrone, and bevacizumab.

Karp JE, Gojo I, Pili R, Gocke CD, Greer J, Guo C, Qian D, Morris L, Tidwell M, Chen H, Zwiebel J.

Clin Cancer Res. 2004 Jun 1;10(11):3577-85.PMID: 15173063 [PubMed - indexed for MEDLINE]Related articlesFree article

Effects of SU5416, a small molecule tyrosine kinase receptor inhibitor, on FLT3 expression and phosphorylation in patients with refractory acute myeloid leukemia.

O'Farrell AM, Yuen HA, Smolich B, Hannah AL, Louie SG, Hong W, Stopeck AT, Silverman LR, Lancet JE, Karp JE, Albitar M, Cherrington JM, Giles FJ.

Leuk Res. 2004 Jul;28(7):679-89.PMID: 15158089 [PubMed - indexed for MEDLINE]Related articles

Genomic mechanisms of p210BCR-ABL signaling: induction of heat shock protein 70 through the GATA response element confers resistance to paclitaxel-induced apoptosis.

Ray S, Lu Y, Kaufmann SH, Gustafson WC, Karp JE, Boldogh I, Fields AP, Brasier AR.

J Biol Chem. 2004 Aug 20;279(34):35604-15. Epub 2004 May 21.PMID: 15155749 [PubMed - indexed for MEDLINE]Related articlesFree article